Cancer gene analysis of liquid‐based cytology specimens using next‐generation sequencing: A technical report of bimodal DNA‐ and RNA‐based panel application

Abstract

AbstractBackgroundAs liquid‐based cytology (LBC) specimens harbor high‐quality DNA, genomic analysis using LBC specimens is beneficial for integrative diagnosis. This study aimed to clarify the feasibility of LBC specimens for a bimodal application of DNA‐ and RNA‐based next‐generation sequencing (NGS) panels.MethodsLBC specimens were prepared from cultured human cancer HEC59 cells using commercially available fixatives (Cellprep, CytoRich Red, and SurePath solutions), and were subjected to NGS for a feasibility study. Clinical LBC specimens of thyroid and salivary gland tumors were prepared using CytoRich Red solution. After DNA and RNA extraction, NGS analyses were performed in a single run using combined DNA‐ and RNA‐based custom‐made cancer panels for the detection of gene mutations and fusions.ResultsHigh‐quality DNA and RNA were obtained, and the expected gene mutations and fusions were detected in HEC59 cells using all types of LBC fixatives. Most available clinical cases (18 out of 20) exhibited pathogenic gene mutations (15 cases) and fusion genes (3 cases) using the bimodal DNA‐ and RNA‐based panels. Overall, 18 cases (90%) showed oncogenic mutations or fusion genes of diagnostic values.ConclusionSimultaneous application of bimodal DNA‐ and RNA‐based gene panels was useful in NGS analysis using residual LBC specimens for integrative diagnosis. Residual LBC specimens for genomic analysis, including fusion gene analysis, are particularly useful for obtaining genomic information before surgical resection.